Ceftazidime-Avibactam for Carbapenem-Resistant Gram-Negative Bacteria Infections: A Real-World Experience in the ICU

References

• Babiker A, Clarke LG, Saul M, et al. Changing epidemiology and decreased mortality associated with carbapenem-resistant gram-negative bacteria, 2000–2017. Clin Infect Dis. 2021;73(11):e4521–e4530. doi:10.1093/cid/ciaa1464
   PubMed Web of Science ®Google Scholar
• Nordmann P, Poirel L. Epidemiology and diagnostics of carbapenem resistance in gram-negative bacteria. Clin Infect Dis. 2019;69(Suppl 7):S521–s528. doi:10.1093/cid/ciz824
   PubMed Web of Science ®Google Scholar
• Tängdén T, Ramos Martín V, Felton TW, et al. The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections. Intensive Care Med. 2017;43(7):1021–1032. doi:10.1007/s00134-017-4780-6
   PubMed Web of Science ®Google Scholar
• Tuon FF, Aragao BZ, Santos TA, Gasparetto J, Cordova K, Abujamra M. Acute kidney injury in patients using amikacin in an era of carbapenem-resistant bacteria. Infect Dis. 2016;48(11–12):869–871. doi:10.1080/23744235.2016.1205215
   PubMed Web of Science ®Google Scholar
• Karakonstantis S, Kritsotakis EI, Gikas A. Pandrug-resistant Gram-negative bacteria: a systematic review of current epidemiology, prognosis and treatment options. J Antimicrob Chemother. 2020;75(2):271–282. doi:10.1093/jac/dkz401
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics; 2017. Available from: https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed. Accessed 16, Mar 2018.
   Google Scholar
• Falcone M, Paterson D. Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections. J Antimicrob Chemother. 2016;71(10):2713–2722. doi:10.1093/jac/dkw239
   PubMed Web of Science ®Google Scholar
• Shirley M. Ceftazidime-avibactam: a review in the treatment of serious gram-negative bacterial infections. Drugs. 2018;78(6):675–692. doi:10.1007/s40265-018-0902-x
   PubMed Web of Science ®Google Scholar
• Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323–2329. doi:10.1001/jama.2009.1754
   PubMed Web of Science ®Google Scholar
• Shields RK, Nguyen MH, Chen L, Press EG, Kreiswirth BN, Clancy CJ. Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections. Antimicrob Agents Chemother. 2018;62(5). doi:10.1128/aac.02497-17
   Web of Science ®Google Scholar
• Chen J, Liang Q, Chen X, et al. Ceftazidime/avibactam versus polymyxin B in the challenge of carbapenem-resistant pseudomonas aeruginosa infection. Infect Drug Resist. 2022;15:655–667. doi:10.2147/idr.S350976
   PubMed Web of Science ®Google Scholar
• Zheng G, Zhang J, Wang B, et al. Ceftazidime-avibactam in combination with in vitro non-susceptible antimicrobials versus ceftazidime-avibactam in monotherapy in critically ill patients with carbapenem-resistant Klebsiella pneumoniae infection: a retrospective cohort study. Infect Dis Ther. 2021;10(3):1699–1713. doi:10.1007/s40121-021-00479-7
   PubMed Web of Science ®Google Scholar
• Instrument of Ceftazidime/Avibactam. 2022. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/206494s011lbl.pdf. Accessed September 06, 2023.
   Google Scholar
• Wang SH, Yang KY, Sheu CC, et al. Efficacies of colistin-carbapenem versus colistin-tigecycline in critically ill patients with CR-GNB-associated pneumonia: a multicenter observational study. Antibiotics. 2021;10:9.
   Google Scholar
• Castón JJ, Gallo M, García M, et al. Ceftazidime-avibactam in the treatment of infections caused by KPC-producing Klebsiella pneumoniae: factors associated with clinical efficacy in a single-center cohort. Int J Antimicrob Agents. 2020;56(3):106075. doi:10.1016/j.ijantimicag.2020.106075
   PubMed Web of Science ®Google Scholar
• Zasowski EJ, Claeys KC, Lagnf AM, Davis SL, Rybak MJ. Time is of the essence: the impact of delayed antibiotic therapy on patient outcomes in hospital-onset enterococcal bloodstream infections. Clin Infect Dis. 2016;62(10):1242–1250. doi:10.1093/cid/ciw110
   PubMed Web of Science ®Google Scholar
• Kollef MH, Shorr AF, Bassetti M, et al. Timing of antibiotic therapy in the ICU. Crit Care. 2021;25(1):360. doi:10.1186/s13054-021-03787-z
   PubMed Web of Science ®Google Scholar
• Balandín B, Ballesteros D, Pintado V, et al. Multicentre study of ceftazidime/avibactam for Gram-negative bacteria infections in critically ill patients. Int J Antimicrob Agents. 2022;59(3):106536. doi:10.1016/j.ijantimicag.2022.106536
   PubMed Web of Science ®Google Scholar
• Zilberberg MD, Shorr AF, Micek ST, Vazquez-Guillamet C, Kollef MH. Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study. Crit Care. 2014;18(6):596. doi:10.1186/s13054-014-0596-8
   PubMed Web of Science ®Google Scholar
• Wenzler E, Bunnell KL, Bleasdale SC, Benken S, Danziger LH, Rodvold KA. Pharmacokinetics and dialytic clearance of ceftazidime-avibactam in a critically ill patient on continuous venovenous hemofiltration. Antimicrob Agents Chemother. 2017;61(7). doi:10.1128/aac.00464-17
   Web of Science ®Google Scholar
• Zhang XS, Wang YZ, Shi DW, et al. Efficacy and pharmacodynamic target attainment for ceftazidime-avibactam off-label dose regimens in patients with continuous or intermittent venovenous hemodialysis: two case reports. Infect Dis Ther. 2022;11(6):2311–2319. doi:10.1007/s40121-022-00621-z
   PubMed Web of Science ®Google Scholar
• Soukup P, Faust AC, Edpuganti V, Putnam WC, McKinnell JA. Steady-state ceftazidime-avibactam serum concentrations and dosing recommendations in a critically ill patient being treated for pseudomonas aeruginosa pneumonia and undergoing continuous venovenous hemodiafiltration. Pharmacotherapy. 2019;39(12):1216–1222. doi:10.1002/phar.2338
   PubMed Web of Science ®Google Scholar
• Bavaro DF, Belati A, Diella L, et al. Loading dose plus continuous/extended infusion versus intermittent bolus of β-lactams for the treatment of Gram-negative bacteria bloodstream infections: a propensity score-adjusted retrospective cohort study. J Antimicrob Chemother. 2023:dkad215. doi:10.1093/jac/dkad215
   Web of Science ®Google Scholar